Halozyme Therapeutics Inc (HALO)

[halofan]

From the Jeffries conference, BMY, John Elicker – Senior Vice President-Corporate Affairs and Head-Investor Relations:

"A couple other things I would reference in that regard. We also think that we have to differentiate ourselves not just with clinical data, so breadth of data is important; but also, for example, you may have seen the deal we recently did with Halozyme during the third quarter, where we have an exclusivity on 11 targets. And as – if you could imagine a future where a lot of these therapies are going to move earlier into the adjuvant setting – AstraZeneca's demonstrated that in lung cancer, we've demonstrated that in melanoma, wouldn't it be great if we could offer the patients in the adjuvant setting or earlier settings, for example, subcutaneous formulation?"

"Not everything we do in the early space plays out, but that’s where we’ve seen opportunities in 2016 and so far in 2017. I mentioned Halozyme earlier. We also bought a private company called IFM, which so – which got distinct asset as well as NLRP program. So you will continue to see us focus on business development as a priority for capital. And it just so happens that within the parameters that I just mentioned, most of the deals we’ve done have tended to be on the smaller scale."

https://seekingalpha.com/article/4125170-bristol-myers-squibb-bmy-presents-jefferies-2017-london-healthcare-conference-transcript?part=single